Portfolio at a glance
Securities as at December 31, 2021
|
Company |
|
Number of securities |
|
Change since 31.12.2020 |
|
Local currency |
|
Share price |
|
Market value in CHF mn |
|
In % of securities |
|
In % of shareholders' equity |
|
In % of company |
|
Moderna |
|
1 663 349 |
|
(1 191 614) |
|
USD |
|
253.98 |
|
385.7 |
|
10.6% |
|
11.7% |
|
0.4% |
|
Argenx SE |
|
970 538 |
|
49 206 |
|
USD |
|
350.19 |
|
310.3 |
|
8.5% |
|
9.5% |
|
1.9% |
|
Ionis Pharmaceuticals |
|
10 232 973 |
|
2 012 973 |
|
USD |
|
30.43 |
|
284.3 |
|
7.8% |
|
8.7% |
|
7.2% |
|
Neurocrine Biosciences |
|
3 015 400 |
|
(19 600) |
|
USD |
|
85.17 |
|
234.5 |
|
6.4% |
|
7.1% |
|
3.2% |
|
Vertex Pharmaceuticals |
|
1 030 000 |
|
130 000 |
|
USD |
|
219.60 |
|
206.5 |
|
5.7% |
|
6.3% |
|
0.4% |
|
Fate Therapeutics |
|
3 701 336 |
|
1 671 336 |
|
USD |
|
58.51 |
|
197.7 |
|
5.4% |
|
6.0% |
|
3.9% |
|
Incyte |
|
2 897 000 |
|
(3 000) |
|
USD |
|
73.40 |
|
194.1 |
|
5.3% |
|
5.9% |
|
1.3% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Alnylam Pharmaceuticals |
|
1 110 000 |
|
(45 000) |
|
USD |
|
169.58 |
|
171.8 |
|
4.7% |
|
5.2% |
|
0.9% |
|
Intra-Cellular Therapies |
|
3 538 419 |
|
– |
|
USD |
|
52.34 |
|
169.1 |
|
4.6% |
|
5.1% |
|
4.3% |
|
Arvinas |
|
2 176 903 |
|
– |
|
USD |
|
82.14 |
|
163.2 |
|
4.5% |
|
5.0% |
|
4.1% |
|
Agios Pharmaceuticals |
|
4 312 292 |
|
153 390 |
|
USD |
|
32.87 |
|
129.4 |
|
3.6% |
|
3.9% |
|
7.9% |
|
Sage Therapeutics |
|
3 170 104 |
|
1 630 000 |
|
USD |
|
42.54 |
|
123.1 |
|
3.4% |
|
3.7% |
|
5.4% |
|
Relay Therapeutics |
|
4 085 962 |
|
2 676 605 |
|
USD |
|
30.71 |
|
114.6 |
|
3.1% |
|
3.5% |
|
3.8% |
|
Biogen |
|
500 000 |
|
(37 000) |
|
USD |
|
239.92 |
|
109.5 |
|
3.0% |
|
3.3% |
|
0.3% |
|
Macrogenics |
|
7 275 564 |
|
2 460 000 |
|
USD |
|
16.05 |
|
106.6 |
|
2.9% |
|
3.2% |
|
11.9% |
|
Myovant Sciences |
|
6 122 039 |
|
1 365 000 |
|
USD |
|
15.57 |
|
87.0 |
|
2.4% |
|
2.6% |
|
6.6% |
|
Revolution Medicines |
|
3 421 462 |
|
3 421 462 |
|
USD |
|
25.17 |
|
78.6 |
|
2.2% |
|
2.4% |
|
4.6% |
|
Kezar Life Sciences |
|
4 918 148 |
|
385 000 |
|
USD |
|
16.72 |
|
75.1 |
|
2.1% |
|
2.3% |
|
9.2% |
|
Crispr Therapeutics |
|
949 584 |
|
48 700 |
|
USD |
|
75.78 |
|
65.7 |
|
1.8% |
|
2.0% |
|
1.2% |
|
Essa Pharma |
|
5 015 814 |
|
5 015 814 |
|
USD |
|
14.20 |
|
65.0 |
|
1.8% |
|
2.0% |
|
11.4% |
|
Scholar Rock Holding |
|
2 275 125 |
|
19 474 |
|
USD |
|
24.84 |
|
51.6 |
|
1.4% |
|
1.6% |
|
6.5% |
|
Radius Health |
|
7 705 714 |
|
250 000 |
|
USD |
|
6.92 |
|
48.7 |
|
1.3% |
|
1.5% |
|
16.3% |
|
Exelixis |
|
2 835 000 |
|
– |
|
USD |
|
18.28 |
|
47.3 |
|
1.3% |
|
1.4% |
|
0.9% |
|
Beam Therapeutics |
|
606 821 |
|
210 000 |
|
USD |
|
79.69 |
|
44.1 |
|
1.2% |
|
1.3% |
|
0.9% |
|
Molecular Templates |
|
10 792 003 |
|
4 411 672 |
|
USD |
|
3.92 |
|
38.6 |
|
1.1% |
|
1.2% |
|
19.2% |
|
Nektar Therapeutics |
|
2 620 676 |
|
– |
|
USD |
|
13.51 |
|
32.3 |
|
0.9% |
|
1.0% |
|
1.4% |
|
Generation Bio Co. |
|
3 853 180 |
|
1 520 000 |
|
USD |
|
7.08 |
|
24.9 |
|
0.7% |
|
0.8% |
|
6.8% |
|
Mersana Therapeutics |
|
4 135 000 |
|
2 250 000 |
|
USD |
|
6.22 |
|
23.5 |
|
0.6% |
|
0.7% |
|
5.8% |
|
Esperion Therapeutics |
|
4 477 964 |
|
530 000 |
|
USD |
|
5.00 |
|
20.4 |
|
0.6% |
|
0.6% |
|
7.1% |
|
Black Diamond Therapeutics |
|
3 440 000 |
|
2 050 000 |
|
USD |
|
5.33 |
|
16.7 |
|
0.5% |
|
0.5% |
|
9.5% |
|
Wave Life Sciences |
|
4 602 858 |
|
2 000 000 |
|
USD |
|
3.14 |
|
13.2 |
|
0.4% |
|
0.4% |
|
7.8% |
|
Homology Medicines |
|
1 737 122 |
|
– |
|
USD |
|
3.64 |
|
5.8 |
|
0.2% |
|
0.2% |
|
3.0% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Alder Biopharmaceuticals – Contingent Value Right |
|
2 766 008 |
|
– |
|
USD |
|
0.88 |
|
2.2 |
|
0.1% |
|
0.1% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total securities |
|
|
|
|
|
|
|
|
|
3 641.1 |
|
100.0% |
|
110.9% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other assets |
|
|
|
|
|
|
|
|
|
3.0 |
|
|
|
0.1% |
|
|
|
Other payables |
|
|
|
|
|
|
|
|
|
(360.6) |
|
|
|
(11.0%) |
|
|
|
Net asset value |
|
|
|
|
|
|
|
|
|
3 283.5 |
|
|
|
100.0% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Exchange rate as at 31.12.2021: USD/CHF: 0.9129